Protagonist Therapeutics Inc

Protagonist Therapeutics Inc

PTGX

Get informed when a big investor buys or sells

+ Follow
Market Cap$7.84B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Protagonist Therapeutics IncProtagonist Therapeutics Inc-67.6--18%--
$117.33

Target Price by Analysts

10.9% downsideProtagonist Therapeutics Target Price DetailsTarget Price
$-4.13

Current Fair Value

103.1% downside

Overvalued by 103.1% based on the discounted cash flow analysis.

Share Statistics

Market cap$7.84 Billion
Enterprise Value$7.66 Billion
Dividend Yield$- (-)
Earnings per Share$-2.05
Beta1.83
Outstanding Shares65,087,847

Return

Return on Equity-17.50%ROE
Return on Assets-16.45%
Return on Invested Capital-20.55%

Valuation & Multiples

P/E Ratio-67.64P/E Ratio
PEG51.06PEG
Price to Sales-Price to Sales
Price to Book Ratio13.16Price to Book Ratio
Enterprise Value to Revenue430.64
Enterprise Value to EBIT-56.23
Enterprise Value to Net Income-67
Total Debt to Enterprise0
Debt to Equity0.02Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
May 6, 2026
EPS Estimate
$-0.65
Average shareholder expectation
Revenue Estimate
$12.20 M
Average shareholder expectation

Next Earnings Call

Expected Date
July 30, 2026
EPS Estimate
$2.06
Average shareholder expectation
Revenue Estimate
$200.53 M
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.2335 17.53%
Total Calls289,900 67.75%
Total Puts67,700 29.45%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %123.87% 12.97%
Total Invested$8.30B 34.34%
Investors Holding331 1.00%

ESG Score

No data

About Protagonist Therapeutics Inc